PTIX
Protagenic Therapeutics, Inc.
Set alert
0.64 USD -0.01 -1.53%
0.6379 Day range 0.6379
0.128 52-week range 2.67
- YTD
- -50.93%
- 1 year
- -75.28%
- Open
- 0.6379
- Prev close
- 0.6478
- Mkt cap
- 1.15M
- Vol
- 118
- Avg vol
- 11.92K
- EPS
- 2.23
- P/E
- 0.29
- Div yield
- 0.00%
More statistics
- Low
- 0.6379
- High
- 0.6379
- Forward P/E
- -0.92
- Beta
- 0.25
- Short ratio
- 1.33
- Inst. own
- 5.77%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 14, 2023
- 50-d avg
- 0.6005
- 200-d avg
- 0.916195
- 1y target
- 0.00
Key statistics
- Market cap
- 3.63M
- Enterprise value
- 1.84M
- Trailing P/E
- 0.00
- Forward P/E
- -0.92
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.65
- EPS (TTM)
- -1.27
- Beta
- 0.25
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -3.12M
- Total cash
- 924.60K
- Total debt
- 0
- Return on equity
- -206.36%
- Shares outstanding
- 6.79M
- Short % of float
- 2.52%
- 50-day average
- 0.6005
- 200-day average
- 0.916195
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
Aug 14, 2023
Expected Aug 14, 2023. Consensus EPS estimate 0.00.
Financials — quick view
PTIX Revenue — quarterly 0
PTIX Net income — quarterly -869.50K
PTIX EPS — quarterly -0.47
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -0.14 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -0.36 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -0.39 | — | — |
| Apr 1, 2024 | Dec 1, 2023 | 0.00 | -0.38 | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | -0.32 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
About Protagenic Therapeutics, Inc.
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- protagenic.com
News
- Protagenic Therapeutics Receives FDA Pre-IND Feedback Supporting New IND for PT00114 in Generalized Anxiety Disorder
- Protagenic Therapeutics' Lead Candidate PT00114 Attenuated Chronic Stress Responses in a Well-Established Rodent Model
- Protagenic Therapeutics Engages Floyd Regulatory Strategic Consulting as Regulatory Affairs Advisor and Danforth Health as Strategic Operations Partner
- Protagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114
- Contrasting Vanda Pharmaceuticals (NASDAQ:VNDA) and Atrinsic (NASDAQ:PTIX)
- Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114
- Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market
- Atrinsic (NASDAQ:PTIX) Shares Up 10.9% – Should You Buy?
- Head-To-Head Contrast: Praxis Precision Medicines (NASDAQ:PRAX) versus Atrinsic (NASDAQ:PTIX)
- Results from Phase 1 Multiple-Dose Study of PT00114
Your note
Sign in to keep a note on PTIX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARROW ALEXANDER K | Chief Financial Officer | Purchase | Oct 11, 2023 | 45,815 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Citadel Advisors Llc | 0.57% | 40,909 | 21.87K | Sep 29, 2024 |
| Vanguard Group Inc | 0.46% | 33,166 | 17.73K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.36% | 26,054 | 13.93K | Sep 29, 2024 |
| Osaic Holdings Inc | 0.30% | 21,414 | 11.45K | Sep 29, 2024 |
| State Street Corporation | 0.19% | 13,812 | 7.38K | Sep 29, 2024 |
| Virtu Financial LLC | 0.18% | 13,118 | 7.01K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.45% | 31,996 | 17.11K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.24% | 17,059 | 9.12K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.07% | 5,007 | 2.68K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.05% | 3,289 | 1.76K | Oct 30, 2024 |